Skip to main content

Interim analysis on the variability and stability of cfDNA in the first year post-transplant

Listen to Dr. Matthew Cooper, an Investigator in the ProActive Study, discuss how serial use of Prospera™ provided strong differentiation of patients with allograft stability (low Prospera™ levels) vs patients with an increased risk of rejection (high Prospera™ levels).